Questions and Answers: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer

Featured In: Regulatory News

By Federal Drug Administration Thursday, June 9, 2024

See today's top life science stories and headlines - Sign up now!

newsvine diigo google
slashdot
Share
Loading...

Questions and Answers: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer

On June 9, 2011, the U.S. Food and Drug Administration (FDA) informed the public of new safety information for drugs called 5-alpha reductase inhibitors (5-ARIs). Men who take these drugs may have an increased risk of being diagnosed with a more serious form of prostate cancer (high-grade prostate cancer). The Warnings and Precautions section of the labels for all FDA-approved 5-ARIs have been revised to include information about this risk.

The following questions and answers address potential issues raised by this safety information.

Q1. What are 5-alpha reductase inhibitors (5-ARIs)?

Q2. What is high-grade prostate cancer?

Q3. Why have the labels of all 5-alpha reductase inhibitors (5-ARIs) been revised?

Q4. What data are available on this safety issue?

Q5. Why is the labeling of Propecia being changed when this drug was not included in either study?

Q6. Does FDA believe the benefits of 5-alpha reductase inhibitors (5-ARIs) still outweigh their risks?

Q7. What should men do if they are currently taking 5-alpha reductase inhibitors (5-ARIs)?

Q8. How should men taking 5-alpha reductase inhibitors (5-ARIs) be screened for prostate cancer?

Q9. Are there other medications to treat benign prostatic hyperplasia (BPH) or male pattern baldness?

 

Q1. What are 5-alpha reductase inhibitors (5-ARIs)?

A. 5-alpha-reductase inhibitors (5-ARIs) are a class of prescription medicines primarily used to treat the symptoms of benign prostatic hyperplasia (BPH) in men. BPH is a common condition in men older than 40 and is characterized by an enlarged prostate and symptoms such as frequent urination and difficulty emptying the bladder. Drugs in this class are finasteride (marketed as Proscar [finasteride 5 mg] and Propecia [finasteride 1 mg]) and dutasteride (marketed as Avodart). Dutasteride is also available in combination with tamsulosin under the brand name Jalyn.

Avodart, Jalyn, and Proscar are indicated for the treatment of BPH symptoms in men with an enlarged prostate. Avodart and Proscar are also approved to reduce the risk of urinary retention or surgery related to BPH.

Propecia is only indicated for the treatment of male pattern hair loss in men.

 

Q2. What is high-grade prostate cancer?

A. High-grade prostate cancer is an aggressive type of prostate cancer, meaning it grows and spreads faster compared to low-grade prostate cancer.

High-grade prostate cancer is a serious disease, but accounts for a small portion of all diagnosed prostate cancers.

 

Q3. Why are the labels of all 5-alpha reductase inhibitors (5-ARIs) being revised?

A.  The labels of all 5-alpha reductase inhibitors (5-ARIs) are being revised based on FDA's review of two large studies examining whether these drug products (Proscar, Avodart) reduce the risk of prostate cancer. The studies did find an overall reduction in the risk of lower-grade forms of prostate cancer, but both studies also showed an increased risk of high-grade prostate cancer.

As a result of these two studies, the labels of all FDA-approved 5-ARIs will be revised to include new information that these drug products may increase the risk of high-grade prostate cancer. The product labeling will also state that 5-ARIs are not approved for the prevention of prostate cancer.

 

Q4. What data are available on this safety issue?

A. The data that formed the basis for these labeling changes were based on two large, randomized controlled studies assessing the ability of 5-ARIs to reduce the rate of diagnosis of prostate cancer over a period of 7 years (Proscar) and 4 years (Avodart), respectively, in men at least 50 years of age. The Proscar trial evaluated the use of 5 mg doses of finasteride (Proscar) versus a placebo (sugar pill), and the Avodart trial evaluated the use of 0.5 mg doses of dutasteride (Avodart) versus a placebo, for the reduction of prostate cancer risk.

The trials demonstrated an overall reduction in prostate cancer diagnoses with finasteride and dutasteride treatment (see the Drug Safety Communication Data Summary for more information). This overall reduction was due to a decreased incidence of lower risk forms of prostate cancer. However, both the finasteride trial and the dutasteride trial showed an increased risk of high-grade prostate cancer.

It is important to note that neither trial evaluated 1 mg doses of finasteride (Propecia), used to treat male pattern hair loss.

 

Q5. Why is the labeling of Propecia being changed when this drug was not included in either study?

A. The labeling of Propecia is being changed to reflect the possibility of an increased risk of high-grade prostate cancer because Propecia contains 1 mg of finasteride. Although this is lower than the amount of finasteride in Proscar (5 mg), the active ingredient is the same.

It is still important to note that the applicability of the Avodart and Proscar studies to Propecia is currently unknown. The outcomes of both studies have been added to the Propecia labeling out of caution.

Men taking Propecia for hair loss should talk to their healthcare professional about the risks and benefits of this drug to determine the most appropriate treatment.

 

Q6. Does FDA believe the benefits of 5-alpha reductase inhibitors (5-ARIs) still outweigh their risks?

A. Yes. FDA believes that 5-ARIs remain safe and effective for their approved indications. Proscar and Avodart have been effective in controlling symptoms of benign prostatic hyperplasia (BPH), as well as in reducing the risks of acute urinary retention and the need for surgical intervention related to BPH. Healthcare professionals and patients are still encouraged to discuss the risks and benefits of 5-ARIs when deciding the best treatment for their disease.

FDA will continue its risk/benefit assessment of using 5-ARIs for the treatment for male pattern hair loss and will update the public when additional information is available.

 

Q7. What should men do if they are currently taking 5-alpha reductase inhibitors (5-ARIs)?

A. Men who are currently taking 5-alpha reductase inhibitors (5-ARIs) should consult a healthcare professional to discuss the risks and benefits of these medications. Men should not stop taking their medication unless directed to do so by a healthcare professional.

 

Q8. How should men taking 5-alpha reductase inhibitors (5-ARIs) be screened for prostate cancer?

A. There is no universally accepted screening test for prostate cancer, including high-grade prostate cancer. The most commonly used screening method is prostate-specific antigen (PSA) blood testing combined with a digital (finger) rectal exam. A PSA test checks for elevated serum PSA levels, which may indicate the presence of prostate cancer. A digital rectal exam involves a healthcare professional inserting a lubricated, gloved finger into the rectum to feel for enlargement, hardness or growths. For more information on prostate cancer screening, visit the National Cancer Institute's Prostate Cancer Screening and Testing website at http://www.cancer.gov/cancertopics/screening/prostate.

It is important to note that 5-alpha reductase inhibitors (5-ARIs) decrease serum PSA levels by approximately 50%. Any confirmed increase in PSA in men taking 5-ARIs, even if the value is within the normal range for men not taking 5-ARIs, should be evaluated by a healthcare professional. Men taking 5-ARIs should discuss the need for prostate cancer screening with a healthcare professional.

 

Q9. Are there other medications to treat benign prostatic hyperplasia (BPH) or male pattern baldness?

A. Yes. Another class of medications called alpha-blockers is approved to treat the symptoms of BPH. Medications in the alpha-blocker class include tamsulosin (Flomax), doxazosin (Cardura), terazosin (Hytrin), alfuzosin (Uroxatral), and silodosin (Rapaflo). However, 5-ARIs are the only medications that have been shown to reduce the risk of urinary retention or surgery related to an enlarged prostate.

Minoxidil is a topical product that is available over the counter in various formulations to treat male pattern hair loss.

 

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2 2010

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25 2010

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25 2010

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22 2010

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Evaluation of a New Nano-Type UV-Vis Spectrophotometer

Mar 3

Analysis of one- to four-microliter size samples for nucleic acids has become routine in many life science laboratories. However, until now, available instruments require considerable manipulation of the instrument and sample; some require manually recording the data. The user must typically lower and raise the arm manually, then wipe the sample manually from the target after each analysis. And fiberoptics used in some of these instruments are subject to deterioration.

Production of Recombinant Proteins and Monoclonal Antibodies in Hollow Fiber Bioreactors

Jan 25

While well-understood, robust and convenient, classical batch-style 2-D culture on non-porous supports or 3-D suspension culture in other devices are really not very biologically relevant models. Cell culture conditions can affect the quality of the antibody or protein produced.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6 2010

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13 2010

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11 2010

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2 2010

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1 2010

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

The effect of obesity on the outcome of hip and knee arthroplasty

5 hours ago

The aim of this study was to evaluate the outcome of joint arthroplasty in obese and non-obese patients. We reviewed 2,026 consecutive primary total hip and 535 primary total knee arthroplasties performed for osteoarthritis. Patients were separated into two...

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care

7 hours ago

PURPOSE: In this prospective multi-centre observational cohort study, we investigated the effect of an intensified multidisciplinary pharmaceutical care programme on the adherence of cancer patients treated with capecitabine, a prodrug of fluorouracil. PATIENTS...

Preservation of femoral bone thickness in middle age predicts survival in genetically heterogeneous mice

10 hours ago

To see if age-related changes in bone could predict subsequent lifespan, we measured multiple aspects of femur size and shape at 4, 15 and 24 months of age in genetically heterogeneous mice. Mice whose cortical bone became thicker from 4 to 15 months, associated...

A reverse transcriptase-related protein mediates phage resistance and polymerizes untemplated DNA in vitro.

11 hours ago

Reverse transcriptases (RTs) are RNA-dependent DNA polymerases that usually function in the replication of selfish DNAs such as retrotransposons and retroviruses. Here, we have biochemically characterized a RT-related protein, AbiK, which is required for...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   
Loading...

Free Life Science Industry
Subscriptions

Magazine

wireless week

Newsletters

newsletters

Sign up now



MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11 2010

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter

Information: